Doriano, who holds a PhD in Cell Biology and Biochemistry, joined Cellestia with a wealth of experience from both academia and the pharma industry. Following 10 years of research at the Biozentrum of the University of Basel, Doriano worked for more than 25 years in drug discovery and development at Novartis and PIQUR Therapeutics.
“I have devoted my entire adult life to bringing innovative therapies to cancer patients and will continue my journey with Cellestia´s novel approach to NOTCH-driven cancer. All of my expertise and experience is now focused on making Cellestia´s approach successful.”
He was previously Chief Scientific Officer at PIQUR Therapeutics in Basel, a small company devoted to the development of novel PI3K/mTOR inhibitors (PQR309 in Phase-2). During his career, he contributed personally to the development of Glivec® (Imatinib, Bcr/Abl kinase inhibitor), Tasigna® (Nilotinib, Bcr/Abl kinase inhibitor), Afinitor® (Everolimus, mTOR inhibitor) and many other compounds still in preclinical or clinical development.